My bet would be that they'll continue to look at new genes. And I wouldn't be surprised to see them continue to look at illnesses that fall under they same FDA department as PMS and Pitt Hopkins.
But I think that's their fallback option.
I would like to have heard of what percentage of effort is being placed into the new indications.
My guess would be less than 5% of total company effort right now.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)